Hologic (NASDAQ:HOLX - Get Free Report) had its target price reduced by analysts at Mizuho from $90.00 to $87.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an "outperform" rating on the medical equipment provider's stock. Mizuho's target price would suggest a potential upside of 8.85% from the company's current price.
Several other analysts also recently issued reports on the stock. Leerink Partners decreased their price objective on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Stephens reaffirmed an "overweight" rating and set a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Royal Bank of Canada upped their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a report on Tuesday. Finally, Raymond James upped their target price on shares of Hologic from $93.00 to $95.00 and gave the company an "outperform" rating in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $89.25.
View Our Latest Stock Analysis on HOLX
HOLX traded down $3.79 during midday trading on Tuesday, hitting $79.93. 1,698,416 shares of the company's stock traded hands, compared to its average volume of 1,583,030. The company has a market cap of $18.57 billion, a PE ratio of 27.19, a price-to-earnings-growth ratio of 2.98 and a beta of 0.98. The stock's fifty day simple moving average is $81.06 and its 200-day simple moving average is $78.08. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic has a one year low of $66.93 and a one year high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.89 earnings per share. As a group, equities analysts anticipate that Hologic will post 4.09 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP grew its holdings in Hologic by 22.2% during the 3rd quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider's stock worth $469,000 after acquiring an additional 1,048 shares during the last quarter. Entropy Technologies LP bought a new stake in Hologic during the 3rd quarter worth about $1,025,000. Versor Investments LP bought a new stake in Hologic during the 3rd quarter worth about $1,677,000. Crossmark Global Holdings Inc. grew its holdings in Hologic by 2.2% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,101 shares of the medical equipment provider's stock worth $1,474,000 after acquiring an additional 393 shares during the last quarter. Finally, Covestor Ltd grew its holdings in Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider's stock worth $56,000 after acquiring an additional 133 shares during the last quarter. Institutional investors own 94.73% of the company's stock.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.